| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | May 21, 2025 |
| Accession Number: | 0001104659-25-051364 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | May 21, 2025 |
| Accession Number: | 0001104659-25-051364 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/20/2025 | Buy → Hold | Lake Street | |
| 1/3/2025 | $5.00 → $18.00 | Buy | H.C. Wainwright |
| 3/11/2024 | $5.00 | Buy | H.C. Wainwright |
| 8/21/2023 | $3.00 | Buy | Lake Street |
| 10/21/2022 | $5.00 | Buy | Jefferies |
BOSTON, May 21, 2025 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company focused on the development and commercialization of specialty therapies for specialists and community care providers, that address important medical and public health threats, today announced that the Company has completed its acquisition of Optinose, Inc. (NASDAQ:OPTN). This acquisition broadens Paratek's commercial portfolio which now includes both its flagship antibiotic, NUZYRA® (omadacycline), and Optinose's product XHANCE® (fluticasone propionate). "Adding XHANCE to our portfolio is a pivotal first step in achieving our long-term vision to become a multi‑product specialty
Company reports fourth quarter and full year 2024 XHANCE net revenue of $22.4 million and $78.2 million, increases of 13% and 10% compared to prior year periods Company reports 23% prescription growth from third quarter 2024 to fourth quarter 2024 YARDLEY, Pa., March 26, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter and year ended December 31, 2024, and provided recent operational highlights. Fourth Quarter 2024 and Recent Highlights New Prescriptions (NRx) and Total Prescriptions (TRx)An inflection in prescription demand first
YARDLEY, Pa., March 19, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the cancellation of its earnings conference call for the quarter and full year ended December 31, 2024 that had originally been scheduled for March 20, 2025 at 8:00 a.m. Eastern Time. The call is being cancelled due to the announcement earlier today that Optinose has entered into a definitive agreement to be acquired by Paratek Pharmaceuticals, subject to shareholder and other customary closing conditions. The Company now expects to report results for the three- and twelve-month periods ended D
4 - OptiNose, Inc. (0001494650) (Issuer)
4 - OptiNose, Inc. (0001494650) (Issuer)
4 - OptiNose, Inc. (0001494650) (Issuer)
Lake Street downgraded OptiNose from Buy to Hold
H.C. Wainwright reiterated coverage of OptiNose with a rating of Buy and set a new price target of $18.00 from $5.00 previously
H.C. Wainwright initiated coverage of OptiNose with a rating of Buy and set a new price target of $5.00
YARDLEY, Pa., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the appointment of Terry Kohler as Chief Financial Officer. Mr. Kohler was most recently the Chief Financial Officer for Verrica Pharmaceuticals, a dermatology therapeutics company, where he supported commercial preparations for the launch of a topical treatment for molluscum contagiosum and research and development pipeline investments. Mr. Kohler is an experienced biotech finance leader with over 20 years of business experience. "We are pleased to add Terry to our leadership team to help guide
YARDLEY, Pa., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Peter Miller has stepped down as Chief Executive Officer and Board member, and that Ramy Mahmoud, MD, MPH has been appointed as Chief Executive Officer and Board member. In announcing his departure, Peter Miller shared, "It has been a privilege working with the amazing group of colleagues at Optinose. I am proud of all that we have accomplished and the impact we continue to make in our mission to improve patients' lives." During Mr. Miller's nearly 13 years as CEO, the Company experienced s
YARDLEY, Pa., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the appointment of Paul Spence as Chief Commercial Officer. Mr. Spence was most recently the Senior Vice President of the U.S. Commercial Organization at Nestlé Health Sciences where he built the commercial capabilities for the Aimmune Gastrointestinal and Food Allergy businesses. Mr. Spence has 30 years of experience in the life science and pharmaceuticals industry as a leader responsible for marketing, sales, market access, operations, and supply chain. Prior to joining Nestlé Health Sciences,
SC 13G - OptiNose, Inc. (0001494650) (Subject)
SC 13G/A - OptiNose, Inc. (0001494650) (Subject)
SC 13G/A - OptiNose, Inc. (0001494650) (Subject)
BOSTON, May 21, 2025 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company focused on the development and commercialization of specialty therapies for specialists and community care providers, that address important medical and public health threats, today announced that the Company has completed its acquisition of Optinose, Inc. (NASDAQ:OPTN). This acquisition broadens Paratek's commercial portfolio which now includes both its flagship antibiotic, NUZYRA® (omadacycline), and Optinose's product XHANCE® (fluticasone propionate). "Adding XHANCE to our portfolio is a pivotal first step in achieving our long-term vision to become a multi‑product specialty
YARDLEY, Pa., March 19, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the cancellation of its earnings conference call for the quarter and full year ended December 31, 2024 that had originally been scheduled for March 20, 2025 at 8:00 a.m. Eastern Time. The call is being cancelled due to the announcement earlier today that Optinose has entered into a definitive agreement to be acquired by Paratek Pharmaceuticals, subject to shareholder and other customary closing conditions. The Company now expects to report results for the three- and twelve-month periods ended D
Paratek will accelerate access for XHANCE beyond specialists to primary care providers maximizing the recent label expansion for CRS in a ~10‑million‑patient marketAcquisition advances Paratek's vision to become a multi-product company focused on innovative specialty therapies Total transaction value of up to ~$330 million Potential consideration of up to $14 per share, including upfront consideration of $9 per share, representing a 50% premium to Optinose's closing trading price on March 19, 2025 BOSTON and YARDLEY, Pa., March 19, 2025 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals and Optinose, Inc. (NASDAQ:OPTN) today announced they have entered into a definitive merger agreement under w
EFFECT - OptiNose, Inc. (0001494650) (Filer)
EFFECT - OptiNose, Inc. (0001494650) (Filer)
EFFECT - OptiNose, Inc. (0001494650) (Filer)